Page last updated: 2024-08-24

irinotecan and Blast Crisis

irinotecan has been researched along with Blast Crisis in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bourhis, JH; Damaj, G; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Ravoet, C; Ribrag, V; Suzan, F; Vantelon, JM	1
Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M	1

Trials

1 trial(s) available for irinotecan and Blast Crisis

Article	Year
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukemia, 2003, Volume: 17, Issue:2 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Blast Crisis; Bone Marrow; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Time Factors	2003

Article

Year

Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.

Leukemia, 2003, Volume: 17, Issue:2

Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Blast Crisis; Bone Marrow; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Time Factors

2003

Other Studies

1 other study(ies) available for irinotecan and Blast Crisis

Article	Year
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. European journal of haematology, 2006, Volume: 76, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome	2006

Article

Year

Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.

European journal of haematology, 2006, Volume: 76, Issue:5

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome

2006